1. 1-8 of 8
    1. Brave New World: OCT Angiography A Video: Dr. Reichel Reviews OCTA with Drs. Prenner and Kaiser

      Brave New World: OCT Angiography A Video: Dr. Reichel Reviews OCTA with Drs. Prenner and Kaiser

      Elias Reichel, MD, joined Jonathan L. Prenner, MD, and Richard S. Kaiser, MD, for a recent installment of the Retina Today Journal Club. He answered their questions about an imaging technology that will soon be commercially available: optical coherence tomography angiography (OCTA). Dr. Kaiser noted that when many retina doctors first trained, they relied on fluorescein angiography (FA), which offered a limited view of the fundus, before relying on OCT, which revolutionized the clinic. Soon, OCTA may be the next imaging device that revolutionizes the way retina specialists evaluate retinal anatomy. “Now we’re at a precipice of potentially a ...

      Read Full Article
    2. Optical Coherence Tomography Angiography

      Optical Coherence Tomography Angiography

      A primer on this promising new technology for evaluating retinal vasculature. Optical coherence tomography (OCT) is a commonly used technology that noninvasively generates images of the retina in cross section or in three dimensions. 1-5 Advances in technology have facilitated additional applications of OCT such as phase-sensitive OCT, polarization-sensitive OCT, and spectroscopic OCT. 6 These methods hold the promise of combining structural information with functional imaging capabilities to assess the metabolic state of the retinal tissue. 7 This article reviews recent developments in the use of OCT technology for noninvasive assessment of the retinal vasculature. We refer to this technology ...

      Read Full Article
    3. Findings From Octami Study Published

      Findings From Octami Study Published
      ORPINGTON, United Kingdom, Jul 1, 2010 (GlobeNewswire via COMTEX) -- Michelson Diagnostics Ltd., a leading innovator in Multi-Beam Optical Coherence Tomography (OCT) products for scientific research and healthcare imaging, is pleased to announce that Douglas Anderson OBE FRSE FRSA has joined Michelson as non-executive Director. Anderson is the founder of Optos plc., a medical imaging company listed on the London Stock Exchange. He is currently VP of Global Advocacy of Optos. More than 3,500 Optos retinal scanners have been installed worldwide, and more than 25M advanced retina examinations have been performed to date using Optos technology. Their scanners give practitioners ...
      Read Full Article
      Mentions: Optos
    4. OCTDESI Studies Boston Scientific’s Jactax PES

      OCTDESI Studies Boston Scientific’s Jactax PES
      July 20, 2010—Giulio Guagliumi, MD, et al published findings from OCTDESI (Optical Coherence Tomography Drug-Eluting Stent Investigation), a study of strut coverage and vessel wall response to Jactax (Boston Scientific Corporation, Natick, MA), a new-generation paclitaxel-eluting stent (PES) with an ultrathin biodegradable abluminal polymer. The findings were published online ahead of print in Circulation: Cardiovascular Interventions.
      Read Full Article
    5. Stentys’s Self-Expanding Stent Approved in Europe for ACS

      Stentys’s Self-Expanding Stent Approved in Europe for ACS
      March 5, 2010—Stentys, Inc. (Princeton, NJ) announced that it has received CE Mark approval for its self-expanding and disconnectable stent to treat acute coronary syndromes. According to the company, the self-expanding feature is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute myocardial infarction procedure. The device avoids malapposition because it is continuously applied to the vessel's internal surface even during thrombus and vessel spasm relief. The company intends to expand clinical evaluation with the APPOSITION II clinical study, a randomized trial comparing the Stentys self-expanding stent with a ...
      Read Full Article
    6. Enrollment Begins for Stentys’ Apposition II

      December 4, 2009—Stentys, Inc. (Princeton, NJ) announced the commencement of enrollment in the APPOSITION II clinical study, which is a randomized trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in acute myocardial infarction (AMI) patients. The study’s primary endpoint is stent strut apposition at day 3 postprocedure via extremely high-resolution optical coherence tomography (OCT) imaging. Stefan Verheye, MD, PhD, is principal investigator of APPOSTION II, and Professor Christian Spaulding, MD, PhD, enrolled the study’s first patient at the Cochin Hospital, Descartes University in Paris.
      Read Full Article
    7. Cappella Announces Initiation of Sideguard 3 Study

      vember 16, 2009—Cappella, Inc. (Galway, Ireland) announced commencement of Sideguard 3, an intravascular ultrasound/optical coherence tomography evaluation of the company's Sideguard coronary sidebranch stent and delivery system. This is a European multicenter study to evaluate the vascular response to Sideguard in de novo bifurcation lesions of native coronary arteries. The primary objective of the study is to determine the change in stent area (mm²) and corresponding change in vessel area (mm²) at the carina of the sidebranch during the 6-month follow-up period. Gary S. Mintz, MD, and Akiko Maehara, MD, of the Cardiovascular Research Foundation in New ...
      Read Full Article
    1-8 of 8
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks